Pharmacopeia — Pharmacopeia Drug Discovery — UBS Global Life Sciences Conference 2006
25 slides from Pharmacopeia's conference presentation, Sep 28, 2006

Slide 1: UBS Global Life Sciences Conference
Leslie J. Browne President & CEO UBS Global Life Sciences Conference September 28th, 2006 Discovering excellence, driving clinical success TM

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which exp

Slide 3: Value Drivers - Balanced Risk
Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Strong, sustainable pipeline Leader in developing DARA Dual acting angiotensin and endothelin receptor antagonists for kidney diseases First-in-class DARA on track to file IND in 1Q-07 Deep p

Slide 4: Business Strategy – More Ownership
Selected Indications Partner Retain candidates at least to clinical validation with the option to continue alone to NDA for selected indications or partner for Ph III clinical development Former business Lead Discovery Lead Optimization Preclinical Development Phase 1 Phase 2 Phase 3 Partner Busines

Slide 5: Balancing Risk to Build Value
Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Cephalon Organon Schering-Plough Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Intellectual Property High Value Portfolio Pharmacop

Slide 6: Pharmacopeia Strengths
Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

Slide 7: Internal Programs
Internal Programs Robust Growing Internal Pipeline DARA in preclinical development approaching IND Optimization focused on JAK3, CCR1 and A 2A Preclinical Program Worldwide Rights Lead Generation Optimization Development IND Filing PS433540 Cardiovascular DARA Pharmacopeia PS608504 Transplantation J

Slide 8: DARA – First-in-class
DARA – First-in-class ET-1 ET-1 ET-1 A II A II A II Combines the properties of two marketed cardiovascular product classes in a single molecule Selectively blocks Angiotensin (AT1) and Endothelin (ETA) Strong preclinical and clinical data Potential in resistant hypertensions and chronic renal diseas

Slide 9: Preclinical Results - Hypertension and Heart Failure
ET-1 ET-1 ET-1 A II A II A II Angiotensin II and Endothelin – potent mitogens Vasoconstriction Tissue proliferation/fibrosis Inflammation Preclinical Results - Hypertension and Heart Failure PS433540 (BMS-456567) potent antihypertensive in predictive rat hypertension models (SHR and DOCA) ET 1 and A

Slide 10: PS433540 – Antihypertensive Activity
PS433540 reduces blood pressure more than irbesartan at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Telemeterized Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

Slide 11: Clinical Results – Diabetic nephropathy
ET-1 ET-1 ET-1 A II A II A II Angiotensin II and Endothelin – potent mitogens Vasoconstriction Tissue proliferation/fibrosis Inflammation Clinical Results – Diabetic nephropathy Improved renal hemodynamics Marked decrease in urinary albumin excretion rate and proteinuria in Phase II studies ET 1 and

Slide 12: Chronic Kidney Disease – Medical need
Chronic Kidney Disease – Medical need Progressive disease leading to dialysis and transplant Underlying disease causes Diabetes Hypertension Obesity Glomerulonephritis Cystic kidney – most common causes of end-stage renal disease 20 million in US suffer from chronic kidney disease 5% of US populatio

Slide 13: Chronic Kidney Disease – Current Rx
Chronic Kidney Disease – Current Rx Angiotensin Receptor Blockers Approved Avapro® (irbesartan) and Cozaar® (losartan) ACE Inhihitors recommended Usage in patients Elevated serum creatinine Proteinuria (>300 mg/day) in patients with hypertension Reduces the progression of nephropathy Compounds Under

Slide 14: Current Status
Current Status ARBs approved for diabetic nephropathy Benefit demonstrated for investigational ET blocker in combination with ARB in Phase II trials Opportunity for DARA To file IND by 1Q-07 To evaluate antihypertensive activity in Phase Ib To demonstrate dual activity in humans (ET and ARB) in Ph I

Slide 15: DARA Development Summary
DARA Development Summary Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 3Q-06 File IND 1Q-07 ‘First in man’ dosing 1Q-07 Initiate Phase Ib hypertension study End-07 Initiate Ph II 2H-08

Slide 16: Pharmacopeia Strengths
Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

Slide 17: Proven Track Record of Success
Proven Track Record of Success Significant milestone (~$100MM total) and royalty interests without further Pharmacopeia investment Preclinical Clinical Phase Program Worldwide Rights Lead Generation Optimization Development I II III NDA Filed PS540446 Rheumatoid Arthritis p38 Bristol Myers Squibb PS

Slide 18: Clinical Pipeline Advancing
Clinical Pipeline Advancing Partnered clinical programs approaching Phase II p38 kinase inhibitors for RA with Bristol-Myers Squibb Well tolerated in multiple Phase I trials Currently in Ra patients receiving methotrexate Back up compound entered Phase I study December, 2005 CXCR2 antagonist for COP

Slide 19: Pharmacopeia Strengths
Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

Slide 20: Strategic Partnerships
Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase I and Phase II Non-dilutive tranched financing - $15 million Up to

Slide 21: Pharmacopeia Strengths
Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

Slide 22: Financial Summary
Financial Summary For the 6 Months Ended June 30, 2006 $7.4 million in net revenue $14.9 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31 st , 2005 $40.1 million as of June 30, 2006 Received $20 million of f

Slide 23: Milestones from January 2006
Milestones from January 2006 Within 12-months Two internal candidates in pre-clinical development One or more partnered programs in clinical Phase II Strategic partnership with significant retained rights Core clinical-regulatory capability added Year end cash and short term investments of $30-35MM

Slide 24: Pharmacopeia Transformed
Pharmacopeia Transformed DARA approaching IND First-in-class treatment in large markets – IND 1Q-07 Partnered clinical programs approaching Phase II p38 kinase inhibitor for RA with Bristol-Myers Squibb CXCR2 antagonist for COPD with Schering-Plough Portfolio of programs for immunological diseases J

Slide 25: Discovering excellence, driving clinical success
Discovering excellence, driving clinical success TM
Source: SEC EDGAR · 8-K filed Sep 28, 2006
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008